MBTPS1 and COVID-19: This would help assess the feasibility of S1P pathway modulation to help limit the respiratory distress and inflammation in COVID‐19 patients, since S1P1R agonist has proven successful to treat mice from ARDS during fatal H1N1 infections (Zhao et al,2019).